Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 1Neoplasms 1Cancer Pain 1Breakthrough Pain 1

Interventions

Fentanyl 19Analgesia 15Acupuncture Therapy 13Oxycodone 12Zoledronic Acid 11Surveys and Questionnaires 10nabiximols 9Therapeutics 9Morphine 9Acetaminophen 9Psychiatric Rehabilitation 8Ketamine 8Hydromorphone 7Lidocaine 6Ibandronic Acid 6Radiotherapy 5Early Intervention, Educational 5Bupivacaine 5Analgesics, Opioid 5Yoga 4Transcutaneous Electric Nerve Stimulation 4Therapeutic Touch 4Ropivacaine 4Music Therapy 4Methadone 4Massage 4Aromatherapy 4alvimopan 3Tapentadol 3Saline Solution 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pain × Ultracet × Clear all
NCT00576173 2010-04-28

An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

Johnson & Johnson Taiwan Ltd

Phase 4 Completed
60 enrolled

Cancer Pain, Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡